Literature DB >> 25423566

miR-219-5p modulates cell growth of papillary thyroid carcinoma by targeting estrogen receptor α.

Chen Huang1, Zhaogeng Cai, Mingzhu Huang, Chaoming Mao, Qifa Zhang, Yi Lin, Xiaomei Zhang, Bi Tang, Yuqing Chen, Xiaojing Wang, Zhongqing Qian, Lei Ye, Yongde Peng, Huanbai Xu.   

Abstract

CONTEXT: Papillary thyroid carcinoma (PTC) is the most common endocrine malignancy. It has been demonstrated that micro-RNAs (miRNAs) are involved in the development of PTC. The miRNA-chromatin immunoprecipitation microarray assay revealed down-regulation of miR-219-5p; however, the effect of miR-219-5p on PTC cell growth remains unknown. This result implied the critical role of miR-219-5p in the development of PTC.
METHODS: We investigated the association between miR-219-5p and PTC development. Expression of miR-219-5p was monitored in 30 PTC tissue specimens and compared with that in 30 normal thyroid tissue specimens. The effect of miR-219-5p on PTC development was studied by cell proliferation, migration, and apoptosis assays. The underlying mechanism was clarified by a reporter assay and rescue experiment.
RESULTS: The current study confirmed that miR-219-5p expression was inhibited in PTC tissue samples. There were statistically significant differences in the expression of miR-219-5p with regard to sex, tumor size, and lymph node metastasis in patients with PTC. Forced expression of miR-219-5p suppressed PTC cell proliferation and migration and promoted apoptosis. Further study showed that estrogen receptor (ER) α was the direct target of miR-219-5p and mediated the effect of miR-219-5p on PTC occurrence. Expression of miR-219-5p was inversely correlated with that of ERα. Importantly, ERα overexpression in PTC cells rescued the inhibitory effect of miR-219-5p on PTC cell proliferation and migration. Thus, our results indicated that miR-219-5p played a critical role in PTC growth by inhibiting ERα.
CONCLUSION: Our investigation identified miR-219-5p as a negative regulator of PTC development through targeting of ERα.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 25423566      PMCID: PMC4318892          DOI: 10.1210/jc.2014-2883

Source DB:  PubMed          Journal:  J Clin Endocrinol Metab        ISSN: 0021-972X            Impact factor:   5.958


  26 in total

Review 1.  RET/PTC rearrangements and BRAF mutations in thyroid tumorigenesis.

Authors:  Raffaele Ciampi; Yuri E Nikiforov
Journal:  Endocrinology       Date:  2006-08-31       Impact factor: 4.736

2.  Estrogens and breast cancer.

Authors:  Charles L Blander
Journal:  N Engl J Med       Date:  2006-04-13       Impact factor: 91.245

3.  The role of microRNA genes in papillary thyroid carcinoma.

Authors:  Huiling He; Krystian Jazdzewski; Wei Li; Sandya Liyanarachchi; Rebecca Nagy; Stefano Volinia; George A Calin; Chang-Gong Liu; Kaarle Franssila; Saul Suster; Richard T Kloos; Carlo M Croce; Albert de la Chapelle
Journal:  Proc Natl Acad Sci U S A       Date:  2005-12-19       Impact factor: 11.205

4.  Estrogen and thyroid-stimulating hormone (TSH) receptors in neoplastic and nonneoplastic human thyroid tissue.

Authors:  O H Clark; P L Gerend; M Davis; P E Goretzki; P G Hoffman
Journal:  J Surg Res       Date:  1985-02       Impact factor: 2.192

Review 5.  Estrogen receptor interaction with estrogen response elements.

Authors:  C M Klinge
Journal:  Nucleic Acids Res       Date:  2001-07-15       Impact factor: 16.971

6.  MicroRNA-146a targets PRKCE to modulate papillary thyroid tumor development.

Authors:  Xiaoping Zhang; Dan Li; Maoquan Li; Meng Ye; Lanbao Ding; Haidong Cai; Da Fu; Zhongwei Lv
Journal:  Int J Cancer       Date:  2013-09-18       Impact factor: 7.396

7.  BRAF mutations and RET/PTC rearrangements are alternative events in the etiopathogenesis of PTC.

Authors:  Paula Soares; Vítor Trovisco; Ana Sofia Rocha; Jorge Lima; Patrícia Castro; Ana Preto; Valdemar Máximo; Tiago Botelho; Raquel Seruca; Manuel Sobrinho-Simões
Journal:  Oncogene       Date:  2003-07-17       Impact factor: 9.867

8.  MicroRNAs (miR)-221 and miR-222, both overexpressed in human thyroid papillary carcinomas, regulate p27Kip1 protein levels and cell cycle.

Authors:  Rosa Visone; Lucia Russo; Pierlorenzo Pallante; Ivana De Martino; Angelo Ferraro; Vincenza Leone; Eleonora Borbone; Fabio Petrocca; Hansjuerg Alder; Carlo Maria Croce; Alfredo Fusco
Journal:  Endocr Relat Cancer       Date:  2007-09       Impact factor: 5.678

Review 9.  Management of papillary and follicular (differentiated) thyroid cancer: new paradigms using recombinant human thyrotropin.

Authors:  E L Mazzaferri; N Massoll
Journal:  Endocr Relat Cancer       Date:  2002-12       Impact factor: 5.678

10.  miR-26a and its target CKS2 modulate cell growth and tumorigenesis of papillary thyroid carcinoma.

Authors:  Mingli Lv; Xiaoping Zhang; Maoquan Li; Quanchi Chen; Meng Ye; Wenqing Liang; Lanbao Ding; Haidong Cai; Da Fu; Zhongwei Lv
Journal:  PLoS One       Date:  2013-07-05       Impact factor: 3.240

View more
  26 in total

Review 1.  MicroRNA Pharmacoepigenetics: Posttranscriptional Regulation Mechanisms behind Variable Drug Disposition and Strategy to Develop More Effective Therapy.

Authors:  Ai-Ming Yu; Ye Tian; Mei-Juan Tu; Pui Yan Ho; Joseph L Jilek
Journal:  Drug Metab Dispos       Date:  2015-11-13       Impact factor: 3.922

2.  Overexpression miR-211-5p hinders the proliferation, migration, and invasion of thyroid tumor cells by downregulating SOX11.

Authors:  Lei Wang; Yan-Feng Shen; Zhi-Min Shi; Xiao-Juan Shang; Dong-Ling Jin; Feng Xi
Journal:  J Clin Lab Anal       Date:  2017-07-13       Impact factor: 2.352

3.  MicroRNA-663 suppresses cell invasion and migration by targeting transforming growth factor beta 1 in papillary thyroid carcinoma.

Authors:  Zhihong Wang; Hao Zhang; Ping Zhang; Wenwu Dong; Liang He
Journal:  Tumour Biol       Date:  2015-12-19

4.  MicroRNA-219-5p exerts tumor suppressor function by targeting ROBO1 in glioblastoma.

Authors:  Yongmei Jiang; Lin Yin; Huirong Jing; Hui Zhang
Journal:  Tumour Biol       Date:  2015-06-17

5.  miR-219-5p suppresses the proliferation and invasion of colorectal cancer cells by targeting calcyphosin.

Authors:  Quhui Wang; Lirong Zhu; Yasu Jiang; Junfei Xu; Feiran Wang; Zhixian He
Journal:  Oncol Lett       Date:  2017-01-04       Impact factor: 2.967

6.  Protective role of microRNA-219-5p inhibitor against spinal cord injury via liver receptor homolog-1/Wnt/β-catenin signaling pathway regulation.

Authors:  Jie Li; Liqiang Li; Yong Shen
Journal:  Exp Ther Med       Date:  2018-02-01       Impact factor: 2.447

7.  Long non-coding RNA TUG1 promotes progression of oral squamous cell carcinoma through upregulating FMNL2 by sponging miR-219.

Authors:  Guangqi Yan; Xue Wang; Mingliang Yang; Li Lu; Qing Zhou
Journal:  Am J Cancer Res       Date:  2017-09-01       Impact factor: 6.166

8.  Associations between DNA methylation and schizophrenia-related intermediate phenotypes - a gene set enrichment analysis.

Authors:  Johanna Hass; Esther Walton; Carrie Wright; Andreas Beyer; Markus Scholz; Jessica Turner; Jingyu Liu; Michael N Smolka; Veit Roessner; Scott R Sponheim; Randy L Gollub; Vince D Calhoun; Stefan Ehrlich
Journal:  Prog Neuropsychopharmacol Biol Psychiatry       Date:  2015-01-15       Impact factor: 5.067

Review 9.  Overlapping nongenomic and genomic actions of thyroid hormone and steroids.

Authors:  Stephen R Hammes; Paul J Davis
Journal:  Best Pract Res Clin Endocrinol Metab       Date:  2015-04-22       Impact factor: 4.690

10.  Expression of estrogen and progesterone receptors in papillary thyroid carcinoma.

Authors:  Mohammad-Reza Jalali-Nadoushan; Reza Amirtouri; Ali Davati; Samaneh Askari; Sepideh Siadati
Journal:  Caspian J Intern Med       Date:  2016
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.